Open Access

EMBO Molecular Medicine, volume 6, issue 3, pages 372-383

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Makarov Vadim ^{1, 2}

Lechartier Benoit ^{2, 3}

Zhang Ming ^{2, 3}

Neres João ^{2, 3}

van der Sar Astrid M. ⁴

Raadsen Susanne A ⁴

Hartkoorn Ruben C ^{2, 3}

Ryabova Olga B. ^{1, 2}

Vocat Anthony ^{2, 3}

Decosterd Laurent A. ⁵

Widmer Nicolas ⁵

Buclin Thierry ⁵

Bitter Wilbert ^{4, 6}

Andries Koen ⁷

Pojer Florence ^{2, 3}

Dyson Paul J ⁸

Cole Stewart T ^{2, 3}

Hide authors affiliations Show authors affiliations: 8 affiliations

Bakh Institute of Biochemistry Russian Academy of Science Moscow Russia |

More Medicines for Tuberculosis (MM4TB) Consortium www.mm4tb.org

Global Health Institute Ecole Polytechnique Fédérale de Lausanne Lausanne Switzerland |

⁴

Department Medical Microbiology and Infection Control VU University Medical Center Amsterdam The Netherlands |

⁵

Division of Clinical Pharmacology CHUV Hôpital Beaumont Lausanne Switzerland |

⁶

Department of Molecular Microbiology VU University Amsterdam The Netherlands |

⁷

Janssen Infectious Diseases Beerse Belgium |

⁸

Institute of Chemical Sciences and Engineering École Polytechnique Fédérale de Lausanne Lausanne Switzerland |

Publication type: Journal Article

Publication date: 2014-02-05

EMBO press

Journal: EMBO Molecular Medicine

Quartile SCImago

Quartile WOS

Impact factor: 11.1

ISSN: 17574676, 17574684

DOI: 10.1002/emmm.201303575

Copy DOI

PubMed ID: 24500695

Molecular Medicine

Abstract

The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical candidate PBTZ169 binds covalently to DprE1. The crystal structure of the DprE1‐PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme. Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB). When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed. A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease. PBTZ169 is thus an attractive drug candidate to treat TB in humans.

By date By citations

Citations by journals

	5 10 15 20 25 30 35
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 31, 10.26% European Journal of Medicinal Chemistry 31 publications, 10.26%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 23, 7.62% Antimicrobial Agents and Chemotherapy 23 publications, 7.62%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 17, 5.63% Journal of Medicinal Chemistry 17 publications, 5.63%
Drug Discovery Today	Drug Discovery Today, 8, 2.65% Drug Discovery Today 8 publications, 2.65%
ACS Medicinal Chemistry Letters	ACS Medicinal Chemistry Letters, 8, 2.65% ACS Medicinal Chemistry Letters 8 publications, 2.65%
Bioorganic and Medicinal Chemistry Letters	Bioorganic and Medicinal Chemistry Letters, 7, 2.32% Bioorganic and Medicinal Chemistry Letters 7 publications, 2.32%
ChemMedChem	ChemMedChem, 6, 1.99% ChemMedChem 6 publications, 1.99%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 5, 1.66% International Journal of Molecular Sciences 5 publications, 1.66%
Biomedicine and Pharmacotherapy	Biomedicine and Pharmacotherapy, 5, 1.66% Biomedicine and Pharmacotherapy 5 publications, 1.66%
Applied Sciences (Switzerland)	Applied Sciences (Switzerland), 4, 1.32% Applied Sciences (Switzerland) 4 publications, 1.32%
Scientific Reports	Scientific Reports, 4, 1.32% Scientific Reports 4 publications, 1.32%
ChemistrySelect	ChemistrySelect, 4, 1.32% ChemistrySelect 4 publications, 1.32%
Chemical Biology and Drug Design	Chemical Biology and Drug Design, 4, 1.32% Chemical Biology and Drug Design 4 publications, 1.32%
MedChemComm	MedChemComm, 4, 1.32% MedChemComm 4 publications, 1.32%
Molecules	Molecules, 3, 0.99% Molecules 3 publications, 0.99%
Frontiers in Cellular and Infection Microbiology	Frontiers in Cellular and Infection Microbiology, 3, 0.99% Frontiers in Cellular and Infection Microbiology 3 publications, 0.99%
Journal of Antibiotics	Journal of Antibiotics, 3, 0.99% Journal of Antibiotics 3 publications, 0.99%
Journal of Biomolecular Structure and Dynamics	Journal of Biomolecular Structure and Dynamics, 3, 0.99% Journal of Biomolecular Structure and Dynamics 3 publications, 0.99%
Bioorganic and Medicinal Chemistry	Bioorganic and Medicinal Chemistry, 3, 0.99% Bioorganic and Medicinal Chemistry 3 publications, 0.99%
ACS Chemical Biology	ACS Chemical Biology, 3, 0.99% ACS Chemical Biology 3 publications, 0.99%
ACS Infectious Diseases	ACS Infectious Diseases, 3, 0.99% ACS Infectious Diseases 3 publications, 0.99%
RSC Advances	RSC Advances, 3, 0.99% RSC Advances 3 publications, 0.99%
Current Pharmaceutical Biotechnology	Current Pharmaceutical Biotechnology, 2, 0.66% Current Pharmaceutical Biotechnology 2 publications, 0.66%
DMM Disease Models and Mechanisms	DMM Disease Models and Mechanisms, 2, 0.66% DMM Disease Models and Mechanisms 2 publications, 0.66%
Future Microbiology	Future Microbiology, 2, 0.66% Future Microbiology 2 publications, 0.66%
Antibiotics	Antibiotics, 2, 0.66% Antibiotics 2 publications, 0.66%
Pharmaceutics	Pharmaceutics, 2, 0.66% Pharmaceutics 2 publications, 0.66%
Pharmaceuticals	Pharmaceuticals, 2, 0.66% Pharmaceuticals 2 publications, 0.66%
Frontiers in Microbiology	Frontiers in Microbiology, 2, 0.66% Frontiers in Microbiology 2 publications, 0.66%

	5 10 15 20 25 30 35

Citations by publishers

	10 20 30 40 50 60 70 80 90
Elsevier	Elsevier, 84, 27.81% Elsevier 84 publications, 27.81%
American Chemical Society (ACS)	American Chemical Society (ACS), 35, 11.59% American Chemical Society (ACS) 35 publications, 11.59%
American Society for Microbiology	American Society for Microbiology, 27, 8.94% American Society for Microbiology 27 publications, 8.94%
Wiley	Wiley, 27, 8.94% Wiley 27 publications, 8.94%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 22, 7.28% Multidisciplinary Digital Publishing Institute (MDPI) 22 publications, 7.28%
Springer Nature	Springer Nature, 20, 6.62% Springer Nature 20 publications, 6.62%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 13, 4.3% Royal Society of Chemistry (RSC) 13 publications, 4.3%
Taylor & Francis	Taylor & Francis, 10, 3.31% Taylor & Francis 10 publications, 3.31%
Bentham Science	Bentham Science, 7, 2.32% Bentham Science 7 publications, 2.32%
Frontiers Media S.A.	Frontiers Media S.A., 7, 2.32% Frontiers Media S.A. 7 publications, 2.32%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 4, 1.32% Public Library of Science (PLoS) 4 publications, 1.32%
Future Medicine	Future Medicine, 3, 0.99% Future Medicine 3 publications, 0.99%
Oxford University Press	Oxford University Press, 3, 0.99% Oxford University Press 3 publications, 0.99%
The Company of Biologists	The Company of Biologists, 2, 0.66% The Company of Biologists 2 publications, 0.66%
Wolters Kluwer Health	Wolters Kluwer Health, 2, 0.66% Wolters Kluwer Health 2 publications, 0.66%
Consilium Medicum	Consilium Medicum, 2, 0.66% Consilium Medicum 2 publications, 0.66%
Editions E D K	Editions E D K, 1, 0.33% Editions E D K 1 publication, 0.33%
International Union of Crystallography (IUCr)	International Union of Crystallography (IUCr), 1, 0.33% International Union of Crystallography (IUCr) 1 publication, 0.33%
Microbiology Society	Microbiology Society, 1, 0.33% Microbiology Society 1 publication, 0.33%
The Royal Society	The Royal Society, 1, 0.33% The Royal Society 1 publication, 0.33%
SAGE	SAGE, 1, 0.33% SAGE 1 publication, 0.33%
Society of Synthetic Organic Chemistry	Society of Synthetic Organic Chemistry, 1, 0.33% Society of Synthetic Organic Chemistry 1 publication, 0.33%
Tuberculosis Association of India	Tuberculosis Association of India, 1, 0.33% Tuberculosis Association of India 1 publication, 0.33%
EMBO press	EMBO press, 1, 0.33% EMBO press 1 publication, 0.33%
Russian Phthisiologists’ Society	Russian Phthisiologists’ Society, 1, 0.33% Russian Phthisiologists’ Society 1 publication, 0.33%
Cambridge University Press	Cambridge University Press, 1, 0.33% Cambridge University Press 1 publication, 0.33%
Center of Pharmaceutical Analytics Ltd	Center of Pharmaceutical Analytics Ltd, 1, 0.33% Center of Pharmaceutical Analytics Ltd 1 publication, 0.33%
Hindawi Limited	Hindawi Limited, 1, 0.33% Hindawi Limited 1 publication, 0.33%
Federal Pulmonology Research Institute FMBA of Russia	Federal Pulmonology Research Institute FMBA of Russia, 1, 0.33% Federal Pulmonology Research Institute FMBA of Russia 1 publication, 0.33%

	10 20 30 40 50 60 70 80 90

We do not take into account publications that without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2014,2015,2016,2017,2018,2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0,0,0,0,0,0],"codes":[0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["","","","","","","","","","",""],"datasets":[{"label":"Citations number","data":[12,21,17,35,32,32,39,31,39,35,8],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["3.97","6.95","5.63","11.59","10.6","10.6","12.91","10.26","12.91","11.59","2.65"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["European Journal of Medicinal Chemistry","Antimicrobial Agents and Chemotherapy","Journal of Medicinal Chemistry","Drug Discovery Today","ACS Medicinal Chemistry Letters","Bioorganic and Medicinal Chemistry Letters","ChemMedChem","International Journal of Molecular Sciences","Biomedicine and Pharmacotherapy","Applied Sciences (Switzerland)","Scientific Reports","ChemistrySelect","Chemical Biology and Drug Design","MedChemComm","Molecules","Frontiers in Cellular and Infection Microbiology","Journal of Antibiotics","Journal of Biomolecular Structure and Dynamics","Bioorganic and Medicinal Chemistry","ACS Chemical Biology","ACS Infectious Diseases","RSC Advances","Current Pharmaceutical Biotechnology","DMM Disease Models and Mechanisms","Future Microbiology","Antibiotics","Pharmaceutics","Pharmaceuticals","Frontiers in Microbiology"],"ids":[8171,17567,3673,23042,360,8828,1430,14627,23951,16650,13767,8021,3569,23868,1770,21709,6099,3040,1162,2045,7781,3100,12036,7874,341,1488,4502,1203,24403],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/ko5EaisKGm66J1hHXtfEgVEeeWb9uOcMofpNuf0a_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp"],"datasets":[{"label":"","data":[31,23,17,8,8,7,6,5,5,4,4,4,4,4,3,3,3,3,3,3,3,3,2,2,2,2,2,2,2],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[10.26,7.62,5.63,2.65,2.65,2.32,1.99,1.66,1.66,1.32,1.32,1.32,1.32,1.32,0.99,0.99,0.99,0.99,0.99,0.99,0.99,0.99,0.66,0.66,0.66,0.66,0.66,0.66,0.66],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","American Chemical Society (ACS)","American Society for Microbiology","Wiley","Multidisciplinary Digital Publishing Institute (MDPI)","Springer Nature","Royal Society of Chemistry (RSC)","Taylor & Francis","Bentham Science","Frontiers Media S.A.","Public Library of Science (PLoS)","Future Medicine","Oxford University Press","The Company of Biologists","Wolters Kluwer Health","Consilium Medicum","Editions E D K","International Union of Crystallography (IUCr)","Microbiology Society","The Royal Society","SAGE","Society of Synthetic Organic Chemistry","Tuberculosis Association of India","EMBO press","Russian Phthisiologists\u2019 Society","Cambridge University Press","Center of Pharmaceutical Analytics Ltd","Hindawi Limited","Federal Pulmonology Research Institute FMBA of Russia"],"ids":[17,40,142,11,202,8,123,18,39,208,344,6949,19,872,32,4944,1381,730,827,259,31,1303,1812,9415,9166,1,7156,6921,5808],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/ko5EaisKGm66J1hHXtfEgVEeeWb9uOcMofpNuf0a_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","","","\/storage\/images\/resized\/xG3oC19920mmFVqkoVEGKGaMCeoalzyvWxPkVox5_medium.webp","\/storage\/images\/resized\/RlMKyKHh4Q2iTSKF38VHwIFW4f6Ke5ChRSXbQHkq_medium.webp","\/storage\/images\/resized\/BHBStD1OkQqtKFRRjS5njgNe7bXCAEgaDQVK7GTA_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/QzzkQMUwda0fYU3txrAv3z24JfXJEjptEQpWMERc_medium.webp","","\/storage\/images\/resized\/1UiI5HycPsvulDeXOySNp0OuaMMmIKfPnsdKPyH0_medium.webp","\/storage\/images\/resized\/PlupWNweJlDkuOzmPmjH4whIQRcICRIJtsqQjYSd_medium.webp","\/storage\/images\/resized\/cF81zWlLdkmYekymGuDcSdvgBGNKaIDoMoeJtHS1_medium.webp","\/storage\/images\/resized\/ewwj5yBvA6wToa4jkXRrcDjN2omUCp6UYltwKhS8_medium.webp","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/kBjrSSTbgDSe3ES92uVIzAPJ0elbKSWjNyLVrCUd_medium.webp"],"datasets":[{"label":"","data":[84,35,27,27,22,20,13,10,7,7,4,3,3,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[27.81,11.59,8.94,8.94,7.28,6.62,4.3,3.31,2.32,2.32,1.32,0.99,0.99,0.66,0.66,0.66,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33,0.33],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Publication PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Makarov V. et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones // EMBO Molecular Medicine. 2014. Vol. 6. No. 3. pp. 372-383.

GOST all authors (up to 50) Copy

Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A. M., Raadsen S. A., Hartkoorn R. C., Ryabova O. B., Vocat A., Decosterd L. A., Widmer N., Buclin T., Bitter W., Andries K., Pojer F., Dyson P. J., Cole S. T. Towards a new combination therapy for tuberculosis with next generation benzothiazinones // EMBO Molecular Medicine. 2014. Vol. 6. No. 3. pp. 372-383.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1002/emmm.201303575

UR - https://doi.org/10.1002%2Femmm.201303575

TI - Towards a new combination therapy for tuberculosis with next generation benzothiazinones

T2 - EMBO Molecular Medicine

AU - Makarov, Vadim

AU - Lechartier, Benoit

AU - Zhang, Ming

AU - Neres, João

AU - van der Sar, Astrid M.

AU - Raadsen, Susanne A

AU - Hartkoorn, Ruben C

AU - Ryabova, Olga B.

AU - Vocat, Anthony

AU - Decosterd, Laurent A.

AU - Widmer, Nicolas

AU - Buclin, Thierry

AU - Bitter, Wilbert

AU - Andries, Koen

AU - Pojer, Florence

AU - Dyson, Paul J

AU - Cole, Stewart T

PY - 2014

DA - 2014/02/05 00:00:00

PB - EMBO press

SP - 372-383

IS - 3

VL - 6

PMID - 24500695

SN - 1757-4676

SN - 1757-4684

ER -

BibTex |

Cite this

BibTex Copy

@article{2014_Makarov,

author = {Vadim Makarov and Benoit Lechartier and Ming Zhang and João Neres and Astrid M. van der Sar and Susanne A Raadsen and Ruben C Hartkoorn and Olga B. Ryabova and Anthony Vocat and Laurent A. Decosterd and Nicolas Widmer and Thierry Buclin and Wilbert Bitter and Koen Andries and Florence Pojer and Paul J Dyson and Stewart T Cole},

title = {Towards a new combination therapy for tuberculosis with next generation benzothiazinones},

journal = {EMBO Molecular Medicine},

year = {2014},

volume = {6},

publisher = {EMBO press},

month = {feb},

url = {https://doi.org/10.1002%2Femmm.201303575},

number = {3},

pages = {372--383},

doi = {10.1002/emmm.201303575}

}

MLA

Cite this

MLA Copy

Makarov, Vadim, et al. “Towards a new combination therapy for tuberculosis with next generation benzothiazinones.” EMBO Molecular Medicine, vol. 6, no. 3, Feb. 2014, pp. 372-383. https://doi.org/10.1002%2Femmm.201303575.

Found error?

Publisher

EMBO press

Journal

EMBO Molecular Medicine

Quartile SCImago

Quartile WOS

Impact factor

11.1

ISSN

17574676 (Print)
17574684 (Electronic)

Labs

Laboratory of Biomedical Chemistry

Profiles

Makarov, Vadim Albertovich